Showing results (291-300 of 352) with videos related to
Sort By:
Pageof 36
Therapeutic Advances in Chronic Disease|November 10, 2025
Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publicationDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.The New England Journal of Medicine|October 19, 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.Human Mutation|August 9, 2005
Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutations in ABCC6Sara Miksch, Amanda Lumsden, Ulf P Guenther, et al.Journal of the American Academy of Dermatology|September 20, 2020
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, et al.The New England Journal of Medicine|March 5, 2025
Remibrutinib in Chronic Spontaneous UrticariaMartin Metz, Ana Giménez-Arnau, Michihiro Hide, et al.Journal of the American Academy of Dermatology|December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panelJoshua Burshtein, April Armstrong, May Chow, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.The Journal of Clinical and Aesthetic Dermatology|January 25, 2021
The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric ComorbiditiesRyan Rivera-Oyola, Roselyn Stanger, Graham H Litchman, et al.The British Journal of Dermatology|January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trialsMark Lebwohl, Richard B Warren, Howard Sofen, et al.Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.Pageof 36